Short answer
ResMed (RMD) filed an 8-K current report with the SEC on April 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Q3 fiscal 2026 results for quarter ended March 31, 2026.
ResMed 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 fiscal 2026 results for quarter ended March 31, 2026
- Press release furnished as Exhibit 99.1 contains operating results and financial details
- Earnings disclosure enables investors to assess quarterly performance once Exhibit 99.1 is reviewed
Item 8.01 · Other Events
- Quarterly dividend declared at $0.60 per share
- May 14, 2026 record date and June 18, 2026 payment date
- May 13, 2026 ex-dividend date for NYSE shares and ASX CDIs
- CDI distributions in Australian dollars reflect the 10:1 CDI-to-share ratio
- ASX settlement waiver temporarily defers share-CDI conversions through May 14, 2026
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $1.431B, up 11% reported and 8% constant currency, led by masks and other products up 15%
- GAAP gross margin expanded 290 bps to 62.2%, supporting 17% operating-income growth to $499.8M
- Non-GAAP diluted EPS rose 21% to $2.86, while GAAP diluted EPS reached $2.74
- Operating cash flow $554M funded $262M in dividends and repurchases, including $175M spent repurchasing 673,000 shares
- Quarterly dividend raised or maintained at $0.60 per share, payable June 18, 2026 to May 14 record-date holders
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ResMed 8-K filings
Get the next RMD 8-K as it lands
Follow RMD for push alerts, or ask the research agent what this filing means.